These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 31963413)

  • 41. Immunotherapy in advanced non-small-cell lung cancer with
    Liu F; Yuan X; Jiang J; Chu Q
    Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Checkpoint Blockade in Lung Cancer and Mesothelioma.
    Lievense LA; Sterman DH; Cornelissen R; Aerts JG
    Am J Respir Crit Care Med; 2017 Aug; 196(3):274-282. PubMed ID: 28252315
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
    Yu T; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dendritic Cell-Based Immunotherapy in Lung Cancer.
    Stevens D; Ingels J; Van Lint S; Vandekerckhove B; Vermaelen K
    Front Immunol; 2020; 11():620374. PubMed ID: 33679709
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trends and advances in tumor immunology and lung cancer immunotherapy.
    Aldarouish M; Wang C
    J Exp Clin Cancer Res; 2016 Sep; 35(1):157. PubMed ID: 27686848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Updates on immunotherapy in non-small cell lung cancer.
    Shimanovsky A; Dasanu CA
    Expert Opin Biol Ther; 2014 Apr; 14(4):411-8. PubMed ID: 24512518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
    Gray SG
    BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
    Lu S; Yu Y; Yang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S21-S30. PubMed ID: 30819828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances in immunotherapy for non-small cell lung cancer.
    Reckamp KL
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):847-53. PubMed ID: 27058851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review.
    Rochigneux P; Garcia AJ; Chanez B; Madroszyk A; Olive D; Garon EB
    Front Immunol; 2020; 11():1036. PubMed ID: 32670271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Immunometabolism Mediated by CD73 Pathway in
    Passarelli A; Aieta M; Sgambato A; Gridelli C
    Front Immunol; 2020; 11():1479. PubMed ID: 32760402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
    Pennell NA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acyl CoA binding protein (ACBP): an autophagy checkpoint that can be targeted for improving cancer immunosurveillance.
    Montégut L; Martins I; Kroemer G
    Oncoimmunology; 2024; 13(1):2413200. PubMed ID: 39381588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.
    Brahmer JR; Pardoll DM
    Cancer Immunol Res; 2013 Aug; 1(2):85-91. PubMed ID: 24777499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
    Jafarnejad M; Gong C; Gabrielson E; Bartelink IH; Vicini P; Wang B; Narwal R; Roskos L; Popel AS
    AAPS J; 2019 Jun; 21(5):79. PubMed ID: 31236847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
    Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
    J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.